Introduction
============

Vogt-Koyanagi-Harada (VKH)syndrome is one of the most common uveitis entities in China \[[@r1]\]. It is characterized by a granulomatous panuveitis frequently in association with extraocular findings such as pleocytosis in the cerebrospinal fluid (CSF), dysacusis, alopecia, poliosis, and vitiligo \[[@r2]-[@r4]\]. Although the exact pathogenesis of VKH syndrome remains unclear, numerous studies have shown that immunogenetic factors are involved in the development of this syndrome. T cells autoreactive against tyrosinase family proteins are possibly involved in VKH syndrome. Meanwhile, genetic factors also play an important role in VKH syndrome as evidenced by the increased rates of this syndrome in pigmented groups \[[@r2]\], familial aggregation \[[@r5]-[@r7]\], and strong association with human leukocyte antigens (*HLA*)-*DR4* and *HLA-DRw53* in various ethnic groups including the Chinese and Japanese \[[@r8]-[@r10]\]. However, little is known about the genes that present susceptibility to the VKH syndrome except *HLA* \[[@r11]-[@r13]\].

Recently, studies have demonstrated that multiple autoimmune diseases may share common susceptibility genes by whole genome association and family based association studies \[[@r14]-[@r17]\]. Therefore, susceptibility genes associated with other autoimmune diseases may be candidates in the study of gene susceptibility to VKH syndrome, an autoimmune uveitis commonly seen in China. Small ubiquitin-like modifier 4 (*SUMO4*) is located on chromosome 6p25. Recently, certain *SUMO4* polymorphisms have been shown to be clearly associated with type 1 diabetes in multiple Asian populations \[[@r18],[@r19]\] as well as with other autoimmune diseases \[[@r19]-[@r22]\], despite controversial observations in Caucasians \[[@r18],[@r23]-[@r25]\]. *SUMO4* polymorphisms could also be involved in the pathogenesis of VKH syndrome, and this hypothesis was therefore the subject of the study presented here.

Methods
=======

Subjects
--------

Blood samples were collected from 231 Chinese Han VKH patients (128 males and 103 females) and 302 age- and sex-matched, unrelated Chinese Han healthy controls (164 males and 138 females), which were recruited from the Uveitis Study Center of the Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, P.R. China and The First Affiliated Hospital, Chongqing Medical University, Chongqing, P.R. China. The institutional ethics committee of Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, P.R. China approved this study, and informed consent was obtained from all tested subjects.

DNA extraction
--------------

Genomic DNA samples were extracted and isolated from ethylene diamine tetraacetic acid (EDTA) anti-coagulated peripheral blood mononuclear cells (PBMCs) of VKH patients and healthy controls by a conventional salting out method. These DNA samples were diluted in PCR grade water and stored at −70 °C until used.

Genotyping
----------

Polymerase chain reaction (PCR) was performed using primers at G-847A locate (Forward, 5′-TCC CAA CCA ATA ATA GCA AGT CT-3′; Reverse, 5′-ATG CCT GGA TCA AAA CAC ACA-3′), A-504G locate (Forward, 5′- TGT GTG TTT TGA TCC AGG CAT TA-3′; Reverse, 5′-TGT TTT GCT CCT CTT TTC CTC TT-3′), A+163G locate (Forward, 5′-ATT GTG AAC CAC GGG GAT TGT TA-3′; Reverse, 5′-CAGCGTTCTGGAGTAAAGAAG-3′), and C+438T locate (Forward, 5′-ATA CCA GTT ACT TCA TGT ATA ATA GA-3′; Reverse, 5′-AGA TTA CTG CAT TCT CAA TTA G −3′). PCR products at G-847A ([rs237026](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=237026)), A-504G ([rs600739](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=600739)), A+163G ([rs237025](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=237025)), and C+438T ([rs237024](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=237024)) loci were incubated with SspI at 37 °C, Alw21I at 37 °C, MseI at 65 °C, and MnlI at 37 °C (MBI Fermentas, Vilnius, Lithuania) for at least 4 h, respectively. PCR fragments were separated on 3% agarose gels. Twenty percent of the PCR samples were directly sequenced to confirm the polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) results (Invitrogen Biotechnology Co., Guangzhou, China). *HLA-DR4* genotyping was performed using the PCR sequence specific primers (SSP) method as previously described \[[@r26]\]. *HLA-DRw53* genotyping was performed as previously described \[[@r27]\].

Statistical analysis
--------------------

The χ^2^ test was applied to analyze the Hardy--Weinberg equilibrium (HWE). The χ^2^ test or Fisher's exact test was performed to compare the allelic, genotypic, and haplotypic distribution between VKH patients and healthy controls using version 12.0 of SPSS for Windows (SPSS Inc., Chicago, IL). Analysis of linkage disequilibrium (LD) of each SNP and haplotype was performed using the [Haploview](http://www.broad.mit.edu/haploview/haploview-downloads) v3.32 program \[[@r28],[@r29]\]. The p values were corrected using the Bonferroni correction to account for multiple testing. Sample sizes were estimated by Quanto 1.2 software (Department of Preventive Medicine, University of Southern California, Los Angles, CA).

Results
=======

Descriptive data of the tested patients and controls
----------------------------------------------------

Detailed clinical findings of the enrolled VKH patients are shown in [Table1](#t1){ref-type="table"}. The average age of the VKH patients was 33.6±12.4 years and that of healthy controls was 35.4±12.0 years. No statistical difference was observed between VKH patients and controls in the distribution of age and gender (p\>0.05).

###### *HLA-DR4* and *HLA-DRw53*distribution and clinical findings of patients with VKH syndrome.

  **Characteristics**      **VKH Patients**                              
  ------------------------ ------------------ ------------ ------------- ------------
  Number of patients (%)   179 (77.5%)        52 (22.5%)   203 (87.9%)   28 (12.1%)
  Male                     103 (80.5%)        25 (19.5%)   116 (90.6%)   12 (9.4%)
  Female                   76 (73.8%)         27 (26.2%)   87 (84.5%)    16 (15.5%)
  Neck stiffness           74 (72.5%)         28 (27.5%)   89 (87.3%)    13 (12.7%)
  Alopecia                 26 (72.2%)         10 (27.8%)   30 (83.3%)    6 (16.7%)
  Poliosis                 65 (73.9%)         23 (26.1%)   78 (88.6%)    10 (11.4%)
  Vitiligo                 41 (74.5%)         14 (25.5%)   48 (87.3%)    7 (12.7%)
  Dysacusia                57 (69.5%)         25 (30.5%)   70 (85.4%)    12 (14.6%)
  Tinnitus                 61 (84.7%)         11 (15.3%)   67 (93.1%)    5 (6.9%)
  Scalp hypersensitivity   32 (74.4%)         11 (25.6%)   38 (88.4%)    5 (11.6%)

The age at onset (years±SD) for all VKH patients was 33.6±12.4 years.

Single nucleotide polymorphism and haplotype analyses between polymorphisms of *SUMO4* and Vogt-Koyanagi-Harada syndrome
------------------------------------------------------------------------------------------------------------------------

The distribution of genotype for each SNP including G-847A, A-504G, A+163G, and C+438T did not deviate from the HWE in VKH patients and healthy controls (p\>0.05). A decreased frequency of *SUMO4* +438 TT genotype was observed in VKH patients compared with healthy controls (p=0.009, χ^2^=9.36). However, it did not remain significant after Bonferroni correction ([Table 2](#t2){ref-type="table"}).

###### The comparison of allele and genotype frequencies for the four polymorphisms of *SUMO4*gene in VKH patients and controls.

  **SNPs**   **Genotype allele**   **VKH n=231 (%)**   **Controls n=302 (%)**   **χ^2^**   **p value**   **pc^a^ value**   **OR** **(95% CI)**
  ---------- --------------------- ------------------- ------------------------ ---------- ------------- ----------------- ---------------------
  −847 G→A   GG                    16 (7.1)            30 (10.1)                3.15       0.207         NS^b^             
  AG         104 (46.0)            116 (39.2)                                                                              
  AA         106 (46.9)            150 (50.7)                                                                              
  G          117 (30.1)            176 (29.7)          2.38                     0.120      NS            1.0 (0.8--1.3)    
  A          343 (69.9)            416 (70.3)                                                                              
  −504 A→G   AA                    54 (24.0)           66 (22.2)                0.25       0.885         NS                
  AG         107 (47.6)            146 (49.2)                                                                              
  GG         64 (28.4)             85 (28.6)                                                                               
  A          215 (47.8)            278 (46.8)          0.10                     0.754      NS            1.0 (0.8--1.3)    
  G          235 (52.2)            316 (53.2)                                                                              
  +163 A→G   AA                    107 (46.5)          145 (48.0)               1.05       0.591         NS                
  AG         107 (46.5)            130 (43.0)                                                                              
  GG         16 (7.0)              27 (8.9)                                                                                
  A          319 (69.7)            420 (69.5)          0.002                    0.968      NS            1.0 (0.8--1.3)    
  G          139 (30.3)            184 (30.5)                                                                              
  +438 C→T   CC                    107 (46.7)          135 (44.7)               9.36       0.009         NS                
  CT         107 (46.7)            122 (40.4)                                                                              
  TT         15 (6.6)              45 (14.9)                                                                               
  C          320 (70.2)            392 (64.9)          3.18                     0.075      NS            1.3 (1.0--1.6)    
  T          136 (29.8)            212 (35.1)                                                                              

^a^ Bonferroni corrected p value; ^b^Not significant.

Haplotype analysis using the [Haploview](http://www.broad.mit.edu/haploview/haploview-downloads) 3.32 software showed that the four SNPs were in strong linkage (D'=84--91). A decreased frequency of *SUMO4* haplotype (−847A, −504G, +163A, and +438T) was observed in VKH patients compared with healthy controls (p=0.008, χ^2^=7.07). However, the significance was lost after Bonferroni correction ([Table 3](#t3){ref-type="table"}).

###### The comparison of frequencies of *SUMO4* haplotypes in VKH Patients and controls.

  **Haplotype**   **VKH n=231 (%)**   **Control n=302 (%)**   **χ^2^**   **p value**   **pc^a^ value**   **OR** **(95% CI)**
  --------------- ------------------- ----------------------- ---------- ------------- ----------------- ---------------------
  AGAC            228.2 (49.8)        274.6 (45.5)            1.99       0.158         NS^b^             1.2 (0.9--1.5)
  GAGT            126.4 (27.6)        156.3 (25.9)            0.40       0.529         NS                1.1 (0.8--1.4)
  AAAC            79.1 (17.3)         101.5 (16.8)            0.04       0.839         NS                1.0 (0.8--1.5)
  AGAT            4.8 (1.0)           21.9 (3.6)              7.07       0.008         NS                0.2 (0.06--0.4)

^a^ Bonferroni corrected p value; ^b^Not significant.

Stratification analysis of *SUMO4* polymorphisms with the status of *HLA-DR4*, *HLA-DRw53*, the clinical findings, and gender
-----------------------------------------------------------------------------------------------------------------------------

Our study showed that the frequency of *HLA-DR4* was significantly increased in 231 VKH patients as compared with that in 302 healthy controls (77.5% versus 19.5%, p=3.21×10^−16^, χ^2^=66.67, OR=13.74, 95% CI=6.99--26.98). *HLA-DRw53* was also shown to be significantly associated with susceptibility to VKH syndrome in the Chinese Han population (87.9% versus 63.9%, p=7.08×10^−5^, χ^2^=15.79, OR=4.13, 95% CI=1.99--8.55). To test whether there was an influence of *HLA-DR4* and *DRw53* on the *SUMO4* association, stratification analysis was performed according to these parameters. The allele and genotype frequencies of the four SNPs of *SUMO4* were not different between *HLA-DR4* positive patients and *HLA-DR4* positive controls and between *HLA-DR4* negative patients and *HLA-DR4* negative controls ([Table 4](#t4){ref-type="table"}). Similar results were also observed in *HLA-DRw53* stratification analysis ([Table 5](#t5){ref-type="table"}). However, a big difference was observed in *HLA-DRw53* negative patients compared with *HLA-DRw53* negative controls (G-847A: AA genotype, *HLA-DRw53*- patients versus *HLA-DRw53*- controls: 40.7% versus 59.4%, AG genotype, *HLA-DRw53*- patients versus *HLA-DRw53*- controls: 48.1% versus 31.1%; A-504G: AA genotype, *HLA-DRw53*- patients versus *HLA-DRw53*- controls: 40.8% versus 21.5%, A allele, *HLA-DRw53*- patients versus *HLA-DRw53*- controls: 59.3% versus 43.9%; A+163G: AA genotype, *HLA-DRw53*- patients versus *HLA-DRw53*- controls: 39.3% versus 56.9%, AG genotype, *HLA-DRw53*- patients versus *HLA-DRw53*- controls: 50.0% versus 33.0%; [Table 5](#t5){ref-type="table"}).

###### Stratification analysis for *HLA-DR4* and *SUMO4* polymorphisms and the comparison of frequencies of *SUMO4*allele and genotype in*HLA-DR4*+ patients versus *HLA-DR4*+ controls and *HLA-DR4*- patients versus *HLA-DR4*- controls.

  **SNPs**   **Genotype allele**   ***HLA-DR4*+ Patients n=179 (%)**   ***HLA-DR4*+ Controls n=59 (%)**   **p value**   **pc^a^ value**   ***HLA-DR4*- Patients n=52 (%)**   ***HLA-DR4*- Controls n=243 (%)**   **p value**   **pc^a^ value**
  ---------- --------------------- ----------------------------------- ---------------------------------- ------------- ----------------- ---------------------------------- ----------------------------------- ------------- -----------------
  −847 G→A   GG                    12 (6.8)                            10 (17.2)                          0.041         NS^b^             4 (8.0)                            20(8.4)                             0.757         NS
  AG         81 (46.0)             20 (34.5)                                                                            23 (46.0)         96 (40.3)                                                                            
  AA         83 (47.2)             28 (48.3)                                                                            23 (46.0)         122 (51.3)                                                                           
  G          105 (29.8)            40 (34.5)                           0.347                              NS            31 (31.0)         136 (28.6)                         0.627                               NS            
  A          247 (70.2)            76 (65.5)                                                                            69 (69.0)         340 (71.4)                                                                           
  −504 A→G   AA                    40 (22.9)                           11 (19.0)                          0.656         NS                14 (28.0)                          55 (23.0)                           0.696         NS
  AG         85 (48.6)             27 (46.6)                                                                            22 (44.0)         119 (49.8)                                                                           
  GG         50 (28.6)             20 (34.5)                                                                            14 (28.0)         65 (27.2)                                                                            
  A          165 (47.1)            49 (42.2)                           0.359                              NS            50 (50.0)         249 (52.1)                         0.703                               NS            
  G          185 (52.9)            67 (57.8)                                                                            50 (50.0)         229 (47.9)                                                                           
  +163 A→G   AA                    84 (46.9)                           29 (49.2)                          0.820         NS                23 (45.1)                          116 (47.7)                          0.872         NS
  AG         83 (46.4)             25 (42.4)                                                                            24 (47.1)         105 (43.2)                                                                           
  GG         12 (6.7)              5 (8.5)                                                                              4 (7.8)           22 (9.1)                                                                             
  A          251 (70.1)            83 (70.3)                           0.963                              NS            70 (68.6)         337 (69.3)                         0.887                               NS            
  G          107 (29.9)            35 (29.7)                                                                            32 (31.4)         149 (30.7)                                                                           
  +438 C→T   CC                    82 (46.3)                           29 (49.2)                          0.089         NS                25 (48.1)                          106 (43.6)                          0.562         NS
  CT         85 (48.0)             22 (37.3)                                                                            22 (42.3)         100 (41.2)                                                                           
  TT         10 (5.6)              8 (13.6)                                                                             5 (9.6)           37 (15.2)                                                                            
  C          249 (70.3)            80 (67.8)                           0.603                              NS            72 (69.2)         312 (64.2)                         0.328                               NS            
  T          105 (29.7)            38 (32.2)                                                                            32 (30.8)         174 (35.8)                                                                           

^a^ Bonferroni corrected p value; ^b^Not significant.

###### Stratification analysis for *HLA-DRw53* and *SUMO4* polymorphisms and the comparison of frequencies of *SUMO4*allele and genotype in*HLA-DRw53*+ patients versus *HLA-DRw53*+ controls and *HLA-DRw53*- patients versus *HLA-DRw53*- controls.

  **SNPs**   **Genotype allele**   ***HLA-DRw53*+ Patients n=203 (%)**   ***HLA-DRw53*+ Controls n=193 (%)**   **p value**   **pc^a^ value**   ***HLA-DRw53*- Patients n=28 (%)**   ***HLA-DRw53*- Controls n=109 (%)**   **p value**   **pc^a^ value**
  ---------- --------------------- ------------------------------------- ------------------------------------- ------------- ----------------- ------------------------------------ ------------------------------------- ------------- -----------------
  −847 G→A   GG                    13 (6.5)                              20 (10.5)                             0.368         NS^b^             3 (11.1)                             10 (9.4)                              0.200         NS
  AG         91 (45.7)             83 (43.7)                                                                                 13 (48.1)         33 (31.1)                                                                                
  AA         95 (47.7)             87 (45.8)                                                                                 11 (40.7)         63 (59.4)                                                                                
  G          117 (29.4)            123 (32.4)                            0.370                                 NS            19 (35.2)         53 (25.0)                            0.133                                 NS            
  A          281 (70.6)            257 (67.6)                                                                                35 (64.8)         159 (75.0)                                                                               
  −504 A→G   AA                    43 (21.7)                             43 (22.6)                             0.742         NS                11 (40.8)                            23 (21.5)                             0.114         NS
  AG         97 (49.0)             98 (51.6)                                                                                 10 (37.0)         48 (44.9)                                                                                
  GG         58 (29.3)             49 (25.8)                                                                                 6 (22.2)          36 (33.6)                                                                                
  A          183 (46.2)            184 (48.4)                            0.538                                 NS            32 (59.3)         94 (43.9)                            0.044                                 NS            
  G          213 (53.8)            196 (51.6)                                                                                22 (40.7)         120 (56.1)                                                                               
  +163 A→G   AA                    96 (47.5)                             83 (43.0)                             0.590         NS                11 (39.3)                            62 (56.9)                             0.216         NS
  AG         93 (46.0)             94 (48.7)                                                                                 14 (50.0)         36 (33.0)                                                                                
  GG         13 (6.4)              16 (8.3)                                                                                  3 (10.7)          11 (10.1)                                                                                
  A          285 (70.5)            260 (67.4)                            0.333                                 NS            36 (64.3)         160 (73.4)                           0.178                                 NS            
  G          119 (29.5)            126 (32.6)                                                                                20 (35.7)         58 (26.6)                                                                                
  +438 C→T   CC                    95 (47.3)                             82 (42.5)                             0.035         NS                12 (42.9)                            53 (48.6)                             0.613         NS
  CT         95 (47.3)             86 (44.6)                                                                                 12 (42.9)         36 (33.0)                                                                                
  TT         11 (5.5)              25 (13.0)                                                                                 4 (14.3)          20 (18.3)                                                                                
  C          285 (70.9)            250 (64.8)                            0.065                                 NS            36 (64.3)         142 (65.1)                           0.905                                 NS            
  T          117 (29.1)            136 (35.2)                                                                                20 (35.7)         76 (34.9)                                                                                

^a^Bonferroni corrected p value; ^b^Not significant.

Stratification analysis was also performed according to clinical findings including neck stiffness, tinnitus, alopecia, poliosis, dysacusis, scalp hypersensitivity, and vitiligo. No association was found between the four SNPs and any extraocular findings. The analysis of gender stratification also showed no association of *SUMO4* polymorphisms with VKH syndrome.

Discussion
==========

In this study, we examined the association of *SUMO4* polymorphisms with VKH syndrome in the Chinese Han population. Our results failed to find an association between *SUMO4* polymorphisms and VKH syndrome even after stratification for *HLA-DR4*, *HLA-DRw53*, clinical features, and gender.

*SUMO4* has been shown to be involved in the regulation of *NF-кB*, an important transcription factor in autoimmune diseases. It has been reported that the *SUMO4* A+163G (M55V) polymorphism is an essential polymorphism involved in regulating its own sumoylation, and it has been shown to be associated with certain autoimmune diseases such as type 1 diabetes, autoimmune thyroid disease, and rheumatoid arthritis without amyloidosis \[[@r19]\]. These results suggest that this polymorphism could be a susceptibility gene shared by certain autoimmune diseases, although conflicting data have been reported in Sjögren's syndrome \[[@r19]\]. The identification of a general susceptibility gene for several autoimmune diseases could make an important contribution to the understanding of the pathogenesis and modulation of these diseases. The question was therefore raised whether the *SUMO4* A+163G polymorphism was also associated with VKH syndrome. This study was designed to clarify this issue. We strictly chose the patients who were definitely diagnosed with VKH syndrome according to the revised criteria \[[@r30]\] to exclude the influence of misdiagnosis. As ethnic confounding could also influence the association results, only VKH patients with Chinese Han nationality as well as age- and sex-matched controls with the same nationality were enrolled in this study. The frequency of the +163G allele in the control population presented in our study is similar with that in the Chinese population reported by Li et al. \[[@r31]\] and in the Japanese population reported by Noso et al. \[[@r20]\]. Meanwhile, a power analysis of the study population showed that our sample size was large enough to detect a possible association. Unexpectedly, we failed to find an association of the *SUMO4* A+163G polymorphism with VKH syndrome. This suggests that this polymorphism may not be involved in the development of susceptibility to VKH syndrome.

Others SNPs including G-847A, A-504G, and C+438T polymorphisms have been identified by direct sequencing of the whole *SUMO4* gene in the Japanese population \[[@r20],[@r32]\]. Our previous results showed an association of *SUMO4* C+438T polymorphism with Behcet's disease \[[@r22]\], another common uveitis entity observed in China. The present study also failed to show any association of the *SUMO4* G-847A, A-504G, and C+438T polymorphisms with VKH syndrome. This difference may result from the different features of these two uveitis entities. One of the striking features of Behcet's disease is its characteristic non-granulomatous inflammation while VKH syndrome is in fact a granulomatous inflammation \[[@r33]\].

Like *HLA-DR4, HLA-DRw53* have been demonstrated to be strongly associated with VKH syndrome. Therefore, genotyping of *HLA-DR4* and *HLA-DRw53* was performed. The association of *HLA-DR4* and *HLA-DRw53* with VKH syndrome was extremely strong in this study. The results were generally consistent with those previously reported in Chinese \[[@r4],[@r8],[@r34]\] and Spanish patients \[[@r35]\]. Furthermore, stratification analysis according to *HLA-DR4* and *HLA-DRw53* did not show any association of *SUMO4* with VKH syndrome in our study. This result is consistent with the previous studies that *SUMO4* M55V polymorphism was independent of the *HLA* class II haplotype \[[@r19],[@r32]\], which is located on the same chromosome 6 as *SUMO4*.

It is worthy to point out that there was a big difference in the percentages of certain alleles and genotypes between *HLA-DRw53* negative patients and controls, although the difference did not reach statistical significance. As the sample size of *HLA-DRw53* negative is small (28 patients), it is necessary to further test the association of *SUMO4* polymorphisms with *HLA-DRw53* negative patients using larger samples.

In conclusion, we failed to detect an association of *SUMO4* polymorphisms with VKH syndrome in Chinese Han population. In agreement with earlier studies, we found a strong association of *HLA-DR4* and *HLA-DRw53* with susceptibility to VKH syndrome. A big but insignificant difference of allele and genotype frequency was noted in *HLA-DRw53* negative patients when compared with *HLA-DRw53* negative controls. Further studies are necessary to elucidate the association of *SUMO4* polymorphisms with VKH syndrome in a *HLA-DRw53* negative population using larger samples.
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